We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

66 hedge funds and large institutions have $226M invested in Protagonist Therapeutics in 2017 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 28 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

833% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 3

460% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 5

61% more funds holding

Funds holding: 41 → 66 (+25)

57% more capital invested

Capital invested by funds: $144M → $226M (+$82.2M)

9.71% more ownership

Funds ownership: 48.08% → 57.79% (+9.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
66
Holders Change
+25
Holders Change %
+60.98%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
28
Increased
28
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
FCM
Farallon Capital Management
California
+$16M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.52M
3
First Manhattan
First Manhattan
New York
+$7.09M
4
BI
BVF Inc
California
+$5.22M
5
DM
Deerfield Management
New York
+$3.99M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$1.77M
2
PC
Polar Capital
United Kingdom
-$1.77M
3
SAM
Senzar Asset Management
New York
-$727K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$178K
5
NFA
Nationwide Fund Advisors
Ohio
-$77K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
51
Wells Fargo
California
$115K -$72.1K -4,065 -42%
CSS
52
Cubist Systematic Strategies
Connecticut
$68K +$57.9K +3,266 New
BNP Paribas Financial Markets
53
BNP Paribas Financial Markets
France
$59.2K +$38.9K +2,190 +333%
SO
54
STRS Ohio
Ohio
$49K – – –
Legal & General Group
55
Legal & General Group
United Kingdom
$46K +$8.64K +487 +28%
Citigroup
56
Citigroup
New York
$36K +$31K +1,750 New
Bank of America
57
Bank of America
North Carolina
$33K +$17.8K +1,005 +166%
Parallax Volatility Advisers
58
Parallax Volatility Advisers
California
$30K +$25.3K +1,428 New
PI
59
Pharmstandard International
Luxembourg
$20.4K – – –
AIP
60
Ameritas Investment Partners
Nebraska
$11K – – –
DCM
61
Delpha Capital Management
New York
$10K +$8.62K +486 New
UBS Group
62
UBS Group
Switzerland
$8K +$1.4K +79 +26%
MAM
63
Meeder Asset Management
Ohio
$8K +$7.11K +401 New
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$1K -$12.2K -687 -91%
PHK
65
Point72 Hong Kong
Hong Kong
$1K +$976 +55 New
RhumbLine Advisers
66
RhumbLine Advisers
Massachusetts
– -$178K -10,096 Closed
NFA
67
Nationwide Fund Advisors
Ohio
– -$77K -4,345 Closed
TRCT
68
Tower Research Capital (TRC)
New York
– -$31K -1,750 Closed
AssetMark Inc
69
AssetMark Inc
California
– +$355 +20 New
1 2
3

PTGX Hedge Fund Activity: Q4 2017 in Review

66 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2017, worth a combined $226M — up 57% from $144M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new PTGX positions and 3 closed out — a net gain of 25 holders — while 28 added to existing stakes and 5 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $16M. The largest seller was Cormorant Asset Management, cutting an estimated $1.77M.

  • 66 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2017, up from 41 in Q3 2017.
  • Funds reported $226M of Protagonist Therapeutics stock for Q4 2017, up 57% quarter-over-quarter.
  • 28 funds opened new Protagonist Therapeutics positions in Q4 2017 and 3 closed out, a net change of +25 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2017 was Farallon Capital Management, an estimated $16M added.
  • The largest Protagonist Therapeutics seller in Q4 2017 was Cormorant Asset Management, an estimated $1.77M sold.

Based on aggregated 13F filings for Q4 2017.